"Thirteenth Five-Year Plan" supports the development stage of innovative and innovative drugs

The 13th five year plan of the pharmaceutical industry is expected to be released by the end of this month, in which encouraging drug innovation will become the key words of the plan According to the industry, the inclusion of innovative drugs in the 13th five year plan shows that the national emphasis on drug research and development has risen to the strategic level, and China's pharmaceutical innovation will usher in a new stage of development Wu Haidong, deputy director of the consumer Industrial Products Department of the Ministry of industry and information technology, said that in the upcoming 13th five year plan for the pharmaceutical industry, the past policies will be adjusted, and the improvement of industrial innovation capacity will be significantly strengthened, and the strength of medical insurance will be further improved to improve the security capacity It is reported that for the reform of the medical insurance payment system, the plan will continue to strengthen the budget management of the medical insurance fund, improve the control of the total amount of medical insurance payment, and form incentives and constraints on medical institutions "Innovation and upgrading of the pharmaceutical industry has become a national strategy, and innovation has become the key word of the 13th five year plan of the pharmaceutical industry Innovation is the key to the transformation of the pharmaceutical industry from large to strong." Said Wu Haidong Wang Hongguang, President of the Development Strategy Research Institute of the Ministry of science and technology, said: "during the 13th Five Year Plan period, major pharmaceutical projects will focus more on core bottleneck technologies to solve those" neck sticking "problems." In drug research and development, the plan focuses on 10 major diseases, including malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, mental diseases, autoimmune diseases, drug-resistant pathogens infection, hepatitis B, AIDS, human infection with avian influenza, and strengthens source innovation and transformation research to create major new drugs Yu Mingde, President of China Pharmaceutical Enterprise Management Association, said, "innovative drugs have been listed in the 13th five year plan, and it can be seen that the national emphasis on drug research and development has risen to the strategic level, and China's pharmaceutical innovation will usher in a new stage of development." Zhang Lianshan, deputy general manager in charge of R & D of Hengrui pharmaceutical, said: "significant changes in the pharmaceutical innovation environment are conducive to promoting the enthusiasm of pharmaceutical enterprises in R & D innovation." In recent years, the state has been promoting the development of drug innovation at all levels, especially the innovation and R & D of major diseases and clinically urgently needed drugs It has successively issued the regulations on the administration of special approval of new drug registration, the description of special approval procedures for biological products, and the work procedure for the priority evaluation of clinically urgently needed generic drugs The promotion of policies has accelerated the application and listing of products in heavyweight fields Taking Hengrui medicine as an example, the company's first-class new drugs, such as iricoxib, apatinib mesylate and other heavy-duty products, are all listed through special approval In addition, Jiangsu Haosen, Zhejiang Haizheng and other special review and approval products are more Industry insiders said that at present, there are different problems in the research and development of many disease drug fields For example, the obstacles in the research and development of children's drugs are not the speed of review and approval, but the difficulty in research and development, including clinical trials and drug pricing "At present, China's domestic R & D and innovation capabilities have made great breakthroughs in many fields In the future, the country's encouragement and support for drug innovation should not only stay at the superficial level such as direct project funding support, but also formulate relevant policies, so that enterprises can see a longer-term development path and prospect, make the environment more transparent and policy planning more clear These are what R & D enterprises need most " Recommended time of 2016 innovative drug development and Cooperation Forum: May 19, 2016 to May 20, 2016 Conference Venue: Hangzhou conference details: http://www.bioon.com/z/2016biopharma/index.shtml